PRESENTERS
Aaron Llanso, Associate Director of Market Development
ABSTRACT
Single-cell sequencing methods have enabled multi-modal characterization of tumor heterogeneity, and yielded novel insights into tumor evolution, therapeutic response & resistance, and measurable residual disease (MRD). Join us for an overview of the Tapestri Platform, and the novel capability to co-detect SNVs, CNVs, and immunophenotype from the same cell with a single, high-throughput workflow.
